Outlook Therapeutics Pursues FDA Dispute Resolution Over Key Retina Drug

Event summary

  • Outlook Therapeutics submitted a formal dispute resolution request (FDRR) to the FDA regarding the Complete Response Letter (CRL) for ONS-5010/LYTENAVA™ (bevacizumab-vikg), received December 30, 2025.
  • The FDA has accepted the FDRR and scheduled a meeting with a deciding official in April 2026.
  • The company believes existing clinical data from NORSE TWO and NORSE EIGHT supports approval.
  • LYTENAVA™ has already received Marketing Authorization in the EU and UK.
  • Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany, Austria, and the UK.

The big picture

Outlook Therapeutics' pursuit of an FDRR highlights the increasing complexity and length of the drug approval process, particularly for biosimilars or follow-on biologics. The company's strategy of pursuing approval in Europe first, then challenging the FDA, is a common tactic to build momentum and potentially influence US regulatory decisions. The success of LYTENAVA™ hinges on demonstrating a clear clinical and commercial advantage over existing anti-VEGF therapies, a crowded and competitive market.

What we're watching

Regulatory Risk
The outcome of the FDA dispute resolution meeting will be critical; a negative decision could significantly impact Outlook's valuation and future development plans.
Commercial Execution
The company's ability to navigate pricing and reimbursement approvals in remaining EU member states will be key to realizing the potential of LYTENAVA™.
Clinical Data
Further scrutiny of the NORSE TWO and NORSE EIGHT trial data is likely, and any new findings could influence the FDA’s decision.